{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:36:42Z","timestamp":1790707002009,"version":"4.1.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Chemoresistance has been a major obstacle to the efficient treatment of cancer. Recently, targeting lipid metabolism has gained significant attention because of its roles not only in promoting cancer progression but also in inducing chemotherapy resistance. Fatty acid synthase (FAS) is the sole enzyme that is in charge of catalyzing the synthesis of palmitate, a long-chain lipid that is essential for membrane construction and post-translational modification in cell biology. Both FAS and its product, palmitate, have been validated as critical players in mediating or causing chemoresistance in cancers, although the details remain elusive, requiring further basic studies. In this mini-review, we provide a brief and concise overview of the basic research on FAS in cancer and its mechanisms of inducing chemoresistance. More importantly, we summarize and critically discuss the progress of small-molecule FAS inhibitors, especially those in clinical trials. While by far, several FAS inhibitors, including denifanstat and omeprazole, have demonstrated beneficial effects in clinical trials, no candidate has been approved by the FDA. We concluded here that targeting FAS is a feasible strategy to overcome chemoresistance, although more interdisciplinary efforts are needed to identify a potent, specific, and bioavailable FAS inhibitor for clinical applications.<\/jats:p>","DOI":"10.3389\/fphar.2025.1674752","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:22:35Z","timestamp":1757586155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Fatty acid synthase in chemoresistance: mechanisms and therapeutic opportunities"],"prefix":"10.3389","volume":"16","author":[{"given":"Li","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10495-017-1366-2","article-title":"Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis","volume":"22","author":"Al-Bahlani","year":"2017","journal-title":"Apoptosis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e8313","DOI":"10.15252\/emmm.201708313","article-title":"Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer","volume":"10","author":"Ali","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/mp700113r","article-title":"Bioavailability of curcumin: problems and promises","volume":"4","author":"Anand","year":"2007","journal-title":"Mol. Pharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1476-511X-9-15","article-title":"Ceramide and ceramide 1-phosphate in health and disease","volume":"9","author":"Arana","year":"2010","journal-title":"Lipids Health Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/path.5587","article-title":"Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by pten loss","volume":"253","author":"Bastos","year":"2021","journal-title":"J. Pathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4161\/cbt.9.1.10392","article-title":"Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer","volume":"9","author":"Bayet-Robert","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"13681","DOI":"10.1021\/acs.jmedchem.2c00642","article-title":"Therapeutic activity of the lansoprazole metabolite 5-Hydroxy lansoprazole sulfide in triple-negative breast cancer by inhibiting the enoyl reductase of fatty acid synthase","volume":"65","author":"Beebe","year":"2022","journal-title":"J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur. Urol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1021\/acschembio.5b00240","article-title":"Diacylglycerol metabolism and signaling is a driving force underlying FASN inhibitor sensitivity in cancer cells","volume":"10","author":"Benjamin","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1182\/blood-2006-02-003988","article-title":"Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells","volume":"109","author":"Bhardwaj","year":"2007","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1709389","DOI":"10.1080\/23723556.2019.1709389","article-title":"Emerging role of fatty acid synthase in tumor initiation: implications for cancer prevention","volume":"7","author":"Bueno","year":"2020","journal-title":"Mol. Cell Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/B978-0-12-394622-5.00010-9","article-title":"Palmitoylation of hedgehog proteins","volume":"88","author":"Buglino","year":"2012","journal-title":"Vitam. Horm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12944-019-1058-8","article-title":"Inhibition of FASN suppresses the malignant biological behavior of non-small cell lung cancer cells via deregulating glucose metabolism and AKT\/ERK pathway","volume":"18","author":"Chang","year":"2019","journal-title":"Lipids Health Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"921985","DOI":"10.3389\/fchem.2022.921985","article-title":"Editorial: novel small-molecule agents in overcoming multidrug resistance in cancers","volume":"10","author":"Cui","year":"2022","journal-title":"Front. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"843829","DOI":"10.3389\/fphar.2022.843829","article-title":"Overexpression of ABCB1 associated with the resistance to the KRAS-G12C specific inhibitor ARS-1620 in cancer cells","volume":"13","author":"Dong","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ijc.22202","article-title":"Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis","volume":"120","author":"Esslimani-Sahla","year":"2007","journal-title":"Int. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1021\/jm501543u","article-title":"Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase","volume":"58","author":"Fako","year":"2015","journal-title":"J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11523-013-0286-5","article-title":"Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase","volume":"9","author":"Fan","year":"2014","journal-title":"Target Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3892\/or.2016.4682","article-title":"Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells","volume":"35","author":"Fan","year":"2016","journal-title":"Oncol. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.3390\/molecules25173935","article-title":"Fatty acid synthase: an emerging target in cancer","volume":"25","author":"Fhu","year":"2020","journal-title":"Molecules"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.bbamem.2017.03.014","article-title":"Emerging role of chemoprotective agents in the dynamic shaping of plasma membrane organization","volume":"1859","author":"Fuentes","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e33738","DOI":"10.1371\/journal.pone.0033738","article-title":"Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma","volume":"7","author":"Gelebart","year":"2012","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"71151","DOI":"10.18632\/oncotarget.9463","article-title":"Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer","volume":"7","author":"Gonzalez-Guerrico","year":"2016","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00280-018-3654-0","article-title":"A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (lipocurc) in patients with locally advanced or metastatic cancer","volume":"82","author":"Greil","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0179692","DOI":"10.1371\/journal.pone.0179692","article-title":"Fatty acid synthase reprograms the epigenome in uterine leiomyosarcomas","volume":"12","author":"Guan","year":"2017","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1039\/c8np00039e","article-title":"The architectures of iterative type I PKS and FAS","volume":"35","author":"Herbst","year":"2018","journal-title":"Nat. Prod. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1158\/1940-6207.CAPR-11-0148","article-title":"Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics","volume":"4","author":"Howells","year":"2011","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.bbalip.2011.09.017","article-title":"Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger?","volume":"1821","author":"Jensen-Urstad","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"B30","doi-asserted-by":"publisher","first-page":"484 e9","DOI":"10.1016\/j.urology.2012.02.046","article-title":"Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer","volume":"80","author":"Jiang","year":"2012","journal-title":"Urology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phymed.2009.09.011","article-title":"Green tea polyphenols for prostate cancer chemoprevention: a translational perspective","volume":"17","author":"Johnson","year":"2010","journal-title":"Phytomedicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-22-2807","article-title":"Phase II investigation of TVB-2640 (denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.2147\/IJN.S256022","article-title":"Fatty acid synthase (FASN) siRNA-Encapsulated-Her-2 targeted fab'-immunoliposomes for gene silencing in breast cancer cells","volume":"15","author":"Khan","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.7150\/ijbs.7357","article-title":"Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells","volume":"10","author":"Li","year":"","journal-title":"Int. J. Biol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"7617","DOI":"10.7314\/apjcp.2014.15.18.7617","article-title":"Mechanism of fatty acid synthase in drug tolerance related to epithelial-mesenchymal transition of breast cancer","volume":"15","author":"Li","year":"","journal-title":"Asian Pac J. Cancer Prev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/1535-7163.MCT-07-0445","article-title":"A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction","volume":"7","author":"Liu","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1194\/jlr.M033811","article-title":"Fatty acid synthase causes drug resistance by inhibiting TNF-alpha and ceramide production","volume":"54","author":"Liu","year":"2013","journal-title":"J. Lipid Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/advances\/nmx011","article-title":"The problem of curcumin and its bioavailability: could its gastrointestinal influence contribute to its overall health-enhancing effects?","volume":"9","author":"Lopresti","year":"2018","journal-title":"Adv. Nutr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.bbalip.2013.07.008","article-title":"Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids","volume":"1831","author":"Louie","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.2147\/OTT.S199369","article-title":"Fatty acid synthase enhances colorectal cancer cell proliferation and metastasis via regulating AMPK\/mTOR pathway","volume":"12","author":"Lu","year":"2019","journal-title":"Onco Targets Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/cmar.s4544","article-title":"Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer","volume":"1","author":"Nguyen","year":"2009","journal-title":"Cancer Manag. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10549-010-1300-6","article-title":"Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase","volume":"130","author":"Pandey","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.3390\/ijms24054476","article-title":"Curcumin supplementation and human disease: a scoping review of clinical trials","volume":"24","author":"Panknin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41586-021-04075-0","article-title":"Dietary palmitic acid promotes a prometastatic memory via schwann cells","volume":"599","author":"Pascual","year":"2021","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/1878-0261.12860","article-title":"Autophagy activation and SREBP-1 induction contribute to fatty acid metabolic reprogramming by leptin in breast cancer cells","volume":"15","author":"Pham","year":"2021","journal-title":"Mol. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10549-007-9678-5","article-title":"Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75","volume":"109","author":"Puig","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"B48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/1471-2407-12-280","article-title":"Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer","volume":"12","author":"Relat","year":"2012","journal-title":"BMC Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e70252","DOI":"10.1002\/mco2.70252","article-title":"Resveratrol: molecular mechanisms, health benefits, and potential adverse effects","volume":"6","author":"Ren","year":"2025","journal-title":"MedComm (2020)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"R431","DOI":"10.1016\/j.cub.2013.04.024","article-title":"Covalent lipid modifications of proteins","volume":"23","author":"Resh","year":"2013","journal-title":"Curr. Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1042\/BST20160233","article-title":"Palmitoylation of proteins in cancer","volume":"45","author":"Resh","year":"2017","journal-title":"Biochem. Soc. Trans."},{"key":"B52","doi-asserted-by":"publisher","first-page":"200414","DOI":"10.1098\/rsob.200414","article-title":"Palmitoylation of hedgehog proteins by hedgehog acyltransferase: roles in signalling and disease","volume":"11","author":"Resh","year":"2021","journal-title":"Open Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/biomedicines6030091","article-title":"Resveratrol: a double-edged sword in health benefits","volume":"6","author":"Salehi","year":"2018","journal-title":"Biomedicines"},{"key":"B54","doi-asserted-by":"publisher","first-page":"100186","DOI":"10.1016\/j.xcrm.2020.100186","article-title":"The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)","volume":"2","author":"Salgia","year":"2021","journal-title":"Cell Rep. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1002\/jcb.25217","article-title":"Global gene deregulations in FASN silenced retinoblastoma cancer cells: molecular and clinico-pathological correlations","volume":"116","author":"Sangeetha","year":"2015","journal-title":"J. Cell Biochem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.1158\/1078-0432.CCR-21-0493","article-title":"Inhibiting fatty acid synthase with omeprazole to improve efficacy of neoadjuvant chemotherapy in patients with operable TNBC","volume":"27","author":"Sardesai","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41523-024-00656-0","article-title":"Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion","volume":"10","author":"Serhan","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.bbadis.2014.11.004","article-title":"Resveratrol and cancer: challenges for clinical translation","volume":"1852","author":"Singh","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1158\/1535-7163.MCT-17-0013","article-title":"Combination treatment with Orlistat-Containing nanoparticles and taxanes is synergistic and enhances microtubule stability in taxane-resistant prostate cancer cells","volume":"16","author":"Souchek","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1021\/acsptsci.3c00182","article-title":"Fatty acid synthase inhibitors enhance microtubule-stabilizing and microtubule-destabilizing drugs in taxane-resistant prostate cancer cells","volume":"6","author":"Souchek","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3390\/cancers13092284","article-title":"Deregulated FASN expression in BRAF inhibitor-resistant melanoma cells unveils new targets for drug combinations","volume":"13","author":"Stamatakos","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/1471-2407-11-360","article-title":"Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population","volume":"11","author":"Stingl","year":"2011","journal-title":"BMC Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3892\/ol.2018.8648","article-title":"Small interfering RNA-mediated knockdown of fatty acid synthase attenuates the proliferation and metastasis of human gastric cancer cells via the mTOR\/Gli1 signaling pathway","volume":"16","author":"Sun","year":"2018","journal-title":"Oncol. Lett."},{"key":"B64","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1158\/0008-5472.CAN-16-3062","article-title":"De novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer","volume":"77","author":"Tadros","year":"2017","journal-title":"Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"101596","DOI":"10.1016\/j.tranon.2022.101596","article-title":"Natural flavonoids exhibit potent anticancer activity by targeting microRNAs in cancer: a signature step hinting towards clinical perfection","volume":"27","author":"Tuli","year":"2023","journal-title":"Transl. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41389-023-00460-8","article-title":"Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies","volume":"12","author":"Vanauberg","year":"2023","journal-title":"Oncogenesis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"11600","DOI":"10.18632\/oncotarget.14591","article-title":"Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells","volume":"8","author":"Wagner","year":"2017","journal-title":"Oncotarget"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1006\/bbrc.2001.5923","article-title":"Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase","volume":"288","author":"Wang","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13046-015-0194-x","article-title":"Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer","volume":"34","author":"Wang","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B70","first-page":"5096","article-title":"Vitisin B as a novel fatty acid synthase inhibitor induces human breast cancer cells apoptosis","volume":"11","author":"Wang","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.03.026","article-title":"Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase","volume":"509","author":"Wang","year":"","journal-title":"Cancer Lett."},{"key":"B72","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"","journal-title":"Drug Resist Updat"},{"key":"B73","doi-asserted-by":"publisher","first-page":"977521","DOI":"10.3389\/fphar.2022.977521","article-title":"Epigallocatechin-3-gallate: a phytochemical as a promising drug candidate for the treatment of Parkinson's disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41467-023-44393-7","article-title":"Surplus fatty acid synthesis increases oxidative stress in adipocytes and lnduces lipodystrophy","volume":"15","author":"Weng","year":"2024","journal-title":"Nat. Commun."},{"key":"B75","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jbior.2013.09.004","article-title":"Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments","volume":"54","author":"Wu","year":"2014","journal-title":"Adv. Biol. Regul."},{"key":"B76","doi-asserted-by":"publisher","first-page":"E6965","DOI":"10.1073\/pnas.1609934113","article-title":"FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-\u03baB and SP1","volume":"113","author":"Wu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3390\/cancers11101523","article-title":"Targeting lysophosphatidic acid in cancer: the issues in moving from bench to bedside","volume":"11","author":"Xu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3892\/ol.2020.12288","article-title":"Fatty acid synthase promotes breast cancer metastasis by mediating changes in fatty acid metabolism","volume":"21","author":"Xu","year":"2021","journal-title":"Oncol. Lett."},{"key":"B79","doi-asserted-by":"publisher","first-page":"543","DOI":"10.12047\/j.cjap.5868.2019.119","article-title":"Effect of down-regulation of fatty acid synthase expression on proliferation, migration and invasion of bladder carcinoma UMUC3 cell lines","volume":"35","author":"Yan","year":"2019","journal-title":"Zhongguo Ying Yong Sheng Li Xue Za Zhi"},{"key":"B80","doi-asserted-by":"publisher","first-page":"107569","DOI":"10.1016\/j.bioorg.2024.107569","article-title":"The cytotoxic natural compound erianin binds to colchicine site of beta-tubulin and overcomes taxane resistance","volume":"150","author":"Yan","year":"2024","journal-title":"Bioorg Chem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"106229","DOI":"10.1016\/j.bioorg.2022.106229","article-title":"Integrated transcriptomics and metabolomics analyses to investigate the anticancer mechanisms of cinobufagin against liver cancer through interfering with lipid, amino acid, carbohydrate, and nucleotide metabolism","volume":"130","author":"Yang","year":"2023","journal-title":"Bioorg Chem."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e8173","DOI":"10.5812\/ijcm.8173","article-title":"Effect of curcumin on fatty acid synthase expression and enzyme activity in breast cancer cell line SKBR3","volume":"10","author":"Younesian","year":"2017","journal-title":"Int. J. Cancer Manag."},{"key":"B83","doi-asserted-by":"publisher","first-page":"6674204","DOI":"10.1155\/2021\/6674204","article-title":"FASN knockdown inhibited anoikis resistance of gastric cancer cells via P-ERK1\/2\/Bcl-xL pathway","volume":"2021","author":"Yu","year":"2021","journal-title":"Gastroenterol. Res. Pract."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1158\/0008-5472.CAN-11-4057","article-title":"Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer","volume":"72","author":"Zaytseva","year":"2012","journal-title":"Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.aohep.2020.03.005","article-title":"Inhibition of fatty acid synthase (FASN) affects the proliferation and apoptosis of HepG2 hepatoma carcinoma cells via the beta-catenin\/C-myc signaling pathway","volume":"19","author":"Zhang","year":"2020","journal-title":"Ann. Hepatol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"113426","DOI":"10.1016\/j.biopha.2022.113426","article-title":"Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer","volume":"153","author":"Zhang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11010-010-0707-z","article-title":"Suppression of fatty acid synthase, differentiation and lipid accumulation in adipocytes by curcumin","volume":"351","author":"Zhao","year":"2011","journal-title":"Mol. Cell Biochem."},{"key":"B88","doi-asserted-by":"publisher","first-page":"106997","DOI":"10.1016\/j.bioorg.2023.106997","article-title":"Recent developments of P-glycoprotein inhibitors and its structure-activity relationship (SAR) studies","volume":"143","author":"Zhao","year":"2024","journal-title":"Bioorg Chem."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3892\/mmr.2015.4746","article-title":"Downregulation of fatty acid synthase complex suppresses cell migration by targeting phosphor-AKT in bladder cancer","volume":"13","author":"Zheng","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"B90","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.13308","article-title":"Protein palmitoylation in cancer: molecular functions and therapeutic potential","volume":"17","author":"Zhou","year":"2023","journal-title":"Mol. Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12967-024-04867-8","article-title":"Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer","volume":"22","author":"Zhou","year":"2024","journal-title":"J. Transl. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1674752\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:22:37Z","timestamp":1757586157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1674752\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":91,"alternative-id":["10.3389\/fphar.2025.1674752"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1674752","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"article-number":"1674752"}}